Search for a trial

APIXABAN FOR THE REDUCTION OF THROMBO-EMBOLISM IN PATIENTS
WITH DEVICE-DETECTED SUB-CLINICAL ATRIAL FIBRILLATION

To determine if the use of apixaban in patients with SCAF will reduce the incidence of stroke and systemic embolism compared to aspirin.

Functional Outcome of Vanguard XP vs CR: a single centre randomized controlled trial using three dimensional fluoroscopic analysis

The primary objective is to compare the Vanguard XP with a CR TKA in terms of kinematics during functional tests using 3D fluoroscopy. The secondary objective is to compare both TKAs in terms of 3D migration of the prosthesis up until 2 years post-…

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or after Platinum-Based Therapy.

The primary objective of this study is to compare the progression-free survival (PFS) of ramucirumab in combination with docetaxel with the PFS of placebo in combination with docetaxel, in patients with locally advanced or unresectable or metastatic…

Fluid hydration to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis: the FLUYT-prevent trial. a multicenter randomized controlled superiority trial.;Pancreatic duct stent placement to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis in patients with unintended PD-wire cannulation: a multicenter prospective cohort

FLUYT: To investigate whether aggressive rehydration with RL during ERCP prevents PEP and will be cost-effective.FLUYT-2-PDS: To investigate if PDS placement further reduce the risk of the development of PEP in patients with unintended PD-wire…

A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab
versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence.

The purpose of this study is to find out if treatment with Nivolumab monotherapy will improve recurrence-free survival (RFS) when compared to Ipilimumab monotherapy in subjects with high risk for recurrence, completely resected Stage III and Stage…